학술논문

Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog®) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study
Document Type
Article
Source
In: BioDrugs. (BioDrugs, November 2022, 36(6):761-772)
Subject
Language
English
ISSN
1179190X
11738804